Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury

Andrew N. Billin
Samuel E. Honeycutt
Alan V. McDougal
Jaclyn P. Kerr
Zhe Chen

See next page for additional authors

10.1186/s13395-018-0185-7

Originally published as:

Original article available here.

This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/5512
Authors
Andrew N. Billin, Samuel E. Honeycutt, Alan V. McDougal, Jaclyn P. Kerr, Zhe Chen, Johannes M. Freudenberg, Deepak K. Rajpal, Guizhen Luo, Henning Fritz Kramer, Robert S. Geske, Frank Fang, Bert Yao, Richard V. Clark, John Lepore, Alex Cobitz, Ram Miller, Kazunori Nosaka, Aaron C. Hinken, and Alan J. Russell

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/5512
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury

Andrew N. Billin¹†, Samuel E. Honeycutt¹†, Alan V. McDougall¹, Jaclyn P. Kerr¹, Zhe Chen¹, Johannes M. Freudenberg³, Deepak K. Rajpal³, Guizhen Luo¹, Henning Fritz Kramer¹, Robert S. Geske³, Frank Fang⁴, Bert Yao², Richard V. Clark¹, John Lepore², Alex Cobitz², Ram Miller¹, Kazunori Nosaka³, Aaron C. Hinken¹ and Alan J. Russell¹*

Correction to: Skeletal Muscle (2018) 8:35

Following publication of the original article [1], the authors flagged that there is a discrepancy with the Availability of data and materials statement on page 12 of the article.

This statement says that “Raw preclinical and clinical data for this manuscript will not be shared for logistical reasons.”

However, the authors state on page 10 of the article that “Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.”

The policy at GlaxoSmithKline, Inc., the sponsor of this paper (see the Funding section on page 12), is consistent with the latter statement, of page 10.

As such, in the interest of full transparency, please be advised that the Availability of data and materials statement on page 12 of the article is void.

Author details
¹Muscle Metabolism Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA, USA. ²Metabolic Pathways and Cardiovascular Therapy Area, GlaxoSmithKline, King of Prussia, PA, USA. ³Target Sciences, GlaxoSmithKline, King of Prussia, PA, USA. ⁴Clinical Statistics, GlaxoSmithKline, King of Prussia, PA, USA. ⁵School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.

* Correspondence: arussell@edgewisetx.com
†Andrew N. Billin and Samuel E. Honeycutt contributed equally to this work.
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.